Voyageur Pharmaceuticals Ltd - Asset Resilience Ratio
Voyageur Pharmaceuticals Ltd (VM) has an Asset Resilience Ratio of 0.15% as of May 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of Voyageur Pharmaceuticals Ltd for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2023)
This chart shows how Voyageur Pharmaceuticals Ltd's Asset Resilience Ratio has changed over time. See Voyageur Pharmaceuticals Ltd shareholders equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Voyageur Pharmaceuticals Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Voyageur Pharmaceuticals Ltd worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 0% |
| Short-term Investments | CA$3.50K | 0.15% |
| Total Liquid Assets | CA$3.50K | 0.15% |
Asset Resilience Insights
- Limited Liquidity: Voyageur Pharmaceuticals Ltd maintains only 0.15% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Voyageur Pharmaceuticals Ltd Industry Peers by Asset Resilience Ratio
Compare Voyageur Pharmaceuticals Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Regencell Bioscience Holdings Ltd
NASDAQ:RGC |
Drug Manufacturers - Specialty & Generic | 43.05% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867 |
Drug Manufacturers - Specialty & Generic | 1.96% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Guobang Pharma Ltd
SHG:605507 |
Drug Manufacturers - Specialty & Generic | 8.47% |
Annual Asset Resilience Ratio for Voyageur Pharmaceuticals Ltd (2021–2023)
The table below shows the annual Asset Resilience Ratio data for Voyageur Pharmaceuticals Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-11-30 | 0.00% | CA$3.50 ≈ $2.53 |
CA$2.16 Million ≈ $1.57 Million |
0.00pp |
| 2022-11-30 | 0.00% | CA$5.95 ≈ $4.30 |
CA$2.10 Million ≈ $1.52 Million |
+0.00pp |
| 2021-11-30 | 0.00% | CA$5.95 ≈ $4.30 |
CA$2.57 Million ≈ $1.86 Million |
-- |
About Voyageur Pharmaceuticals Ltd
Voyageur Pharmaceuticals Ltd., together with its subsidiaries, engages in acquiring, exploring, and developing raw materials for pharmaceutical products in the United States of America, the province of British Columbia, Canada, and the state of Utah. It develops barium and iodine-based APIs. The company offers Smooth HD, Smooth X, Smooth LD, Vision HD, Vision LD, V-Gas, and other products. The co… Read more